


Amendments to the Claims

1. (Currently Amended) A compound according to the formula:



(I)

wherein

G is $\text{CHC}_1\text{-C}_6$ alkyl, C=O , CHOH , CF_2 , C(OH)CF_3 , CHCF_3 , $\text{CH(OH)C}_1\text{-C}_6$ alkyl, $\text{CH-OC}_1\text{-C}_6$ alkyl, $\text{CH-O(CO)C}_1\text{-C}_6$ alkyl, CHF , CHCN , $\text{CHC}_2\text{-C}_4$ alkenyl, $\text{CHC}_2\text{-C}_4$ alkynyl, CHbenzyl , difluoromethylene, O, S(O)_n , wherein n is 0-2; including their enantiomers or a pharmaceutically acceptable salt thereof.

2. (Cancelled)

3. (Currently Amended) A compound selected from the group comprisingconsisting of:

- a) (2*S*, 3*aS*, 4*R*, 9*bR*)-4-(4-Hydroxy-phenyl)-2-methyl-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[c]chromen-8-ol;
- b) (2*R*, 3*aR*, 4*S*, 9*bS*)-4-(4-Hydroxy-phenyl)-2-methyl-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[c]chromen-8-ol;
- c) (2*R*, 3*aR*, 4*S*, 9*bS*)- 2-tert-Butyl-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[c]chromen-8-ol;
- d) (2*S*, 3*aS*, 4*R*, 9*bR*)-2-tert-Butyl-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[c]chromen-8-ol;
- e) (3*aS*, 4*S*, 9*bS*)-4-(4-Hydroxy-phenyl)-1,3*a*,4,9*b*-tetrahydro-3*H*-2,5-dioxa-cyclopenta[a]naphthalen-8-ol;
- f) (3*aR*, 4*R*, 9*bR*)-4-(4-Hydroxy-phenyl)-1,3*a*,4,9*b*-tetrahydro-3*H*-2,5-dioxa-cyclopenta[a]naphthalen-8-ol;

- g) (3a*R*, 4*S*, 9b*S*)-4-(4-Hydroxy-phenyl)-1,3a,4,9b-tetrahydro-3H-5-oxa-2-thia-cyclopenta[*a*]naphthalen-8-ol;
- h) (3a*S*, 4*R*, 9b*R*)-4-(4-Hydroxy-phenyl)-1,3a,4,9b-tetrahydro-3H-5-oxa-2-thia-cyclopenta[*a*]naphthalen-8-ol;
- i) (2*S*, 3a*R*, 4*S*, 9b*S*)-4-(4-Hydroxy-phenyl)-2-oxo-1,2,3,3a,4,9b-hexahydro-5-oxa-2λ⁴-thia-cyclopenta[*a*]naphthalen-8-ol;
- j) (2*R*, 3a*S*, 4*R*, 9b*R*)-4-(4-Hydroxy-phenyl)-2-oxo-1,2,3,3a,4,9b-hexahydro-5-oxa-2λ⁴-thia-cyclopenta[*a*]naphthalen-8-ol;
- k) (3a*R*, 4*S*, 9b*S*)-4-(4-Hydroxy-phenyl)-2,2-dioxo-1,2,3,3a,4,9b-hexahydro-5-oxa-2λ⁶-thia-cyclopenta[*a*]naphthalen-8-ol;
- l) (3a*S*, 4*R*, 9b*R*)-4-(4-Hydroxy-phenyl)-2,2-dioxo-1,2,3,3a,4,9b-hexahydro-5-oxa-2λ⁶-thia-cyclopenta[*a*]naphthalen-8-ol;
- m) (3a*R*, 4*S*, 9b*S*)-8-Hydroxy-4-(4-hydroxy-phenyl)-1,3a,4,9b-tetrahydro-3H-cyclopenta[*c*]chromen-2-one;
- n) (3a*S*, 4*R*, 9b*R*)-8-Hydroxy-4-(4-hydroxy-phenyl)-1,3a,4,9b-tetrahydro-3H-cyclopenta[*c*]chromen-2-one;
- o) (2*S*, 3a*R*, 4*S*, 9b*S*)-4-(4-Hydroxy-phenyl)-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromene-2,8-diol;
- p) (2*R*, 3a*S*, 4*R*, 9b*R*)-4-(4-Hydroxy-phenyl)-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromene-2,8-diol;
- q) (3a*R*, 4*S*, 9b*S*)-2,2-Difluoro-4-(4-hydroxy-phenyl)-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromen-8-ol;
- r) (3a*S*, 4*R*, 9b*R*)-2,2-Difluoro-4-(4-hydroxy-phenyl)-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromen-8-ol;
- s) (2*S*, 3a*R*, 4*S*, 9b*S*)-4-(4-Hydroxy-phenyl)-2-trifluoromethyl-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromen-8-ol;
- t) (2*R*, 3a*S*, 4*R*, 9b*R*)-4-(4-Hydroxy-phenyl)-2-trifluoromethyl-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromen-8-ol;
- u) (2*R*, 3a*S*, 4*S*, 9b*S*)-4-(4-Hydroxy-phenyl)-2-trifluoromethyl-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromen-8-ol;
- v) (2*S*, 3a*S*, 4*R*, 9b*R*)-4-(4-Hydroxy-phenyl)-2-trifluoromethyl-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromen-8-ol;

- w) (2*R*, 3*aR*, 4*S*, 9*bS*)-2-Ethyl-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*bR*-hexahydro-cyclopenta[*c*]chromene-2,8-diol;
- x) (2*S*, 3*aS*, 4*R*, 9*bR*)-2-Ethyl-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*bR*-hexahydro-cyclopenta[*c*]chromene-2,8-diol;
- y) (2*S*, 3*aS*, 4*R*, 9*bR*)-2-Ethyl-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[*c*]chromen-8-ol;
- z) (2*S*, 3*aR*, 4*S*, 9*bS*)-2-Ethyl-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[*c*]chromen-8-ol;
- aa) (2*S*, 3*aR*, 4*S*, 9*bS*)-2-Ethyl-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[*c*]chromen-8-ol;
- bb) (2*R*, 3*aR*, 4*S*, 9*bS*)-2-Ethyl-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[*c*]chromen-8-ol;
- cc) (2*S*, 3*aS*, 4*R*, 9*bR*)-4-(4-Hydroxy-phenyl)-2-methoxy-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[*c*]chromen-8-ol;
- dd) (2*R*, 3*aR*, 4*S*, 9*bS*)-4-(4-Hydroxy-phenyl)-2-methoxy-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[*c*]chromen-8-ol;
- ee) (2*S*, 3*aS*, 4*R*, 9*bR*)-Acetic acid 8-hydroxy-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[*c*]chromen-2-yl ester;
- ff) (2*R*, 3*aR*, 4*S*, 9*bS*)-Acetic acid 8-hydroxy-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[*c*]chromen-2-yl ester;
- gg) (2*R*, 3*aS*, 4*R*, 9*bR*)-2-Fluoro-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[*c*]chromen-8-ol;
- hh) (2*S*, 3*aR*, 4*S*, 9*bS*)-2-Fluoro-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[*c*]chromen-8-ol;
- ii) (2*S*, 3*aS*, 4*R*, 9*bR*)- 2-Fluoro-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[*c*]chromen-8-ol;
- jj) (2*R*, 3*aR*, 4*S*, 9*bS*)-2-Fluoro-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[*c*]chromen-8-ol;
- kk) (2*R*, 3*aR*, 4*S*, 9*bS*)- and (2*S*, 3*aS*, 4*R*, 9*bR*)-8-Hydroxy-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[*c*]chromene-2-carbonitrile;
- ll) (2*S*, 3*aR*, 4*S*, 9*bS*)- and (2*R*, 3*aS*, 4*R*, 9*bR*)-8-Hydroxy-4-(4-hydroxy-phenyl)-1,2,3,3*a*,4,9*b*-hexahydro-cyclopenta[*c*]chromene-2-carbonitrile;

mm) (3a*R*, 4*S*, 9b*S*)- and (3a*S*, 4*R*, 9b*R*)-4-(4-Hydroxy-phenyl)-2-methylene-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromen-8-ol;

nn) (3a*R*, 4*S*, 9b*S*)- and (3a*S*, 4*R*, 9b*R*)-2-Difluoromethylene-4-(4-hydroxy-phenyl)-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromen-8-ol;

oo) (3a*R*, 4*S*, 9b*S*)- and (3a*S*, 4*R*, 9b*R*)-2-Ethynyl-4-(4-hydroxy-phenyl)-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromen-8-ol;

pp) 2-Butyl-4-(4-hydroxy-phenyl)-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromen-8-ol;


qq) 4-(4-Hydroxy-phenyl)-2-propyl-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromen-8-ol;

rr) 2-Ethyl-4-(4-hydroxy-phenyl)-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromen-8-ol; and

ss) 2-Benzyl-4-(4-hydroxy-phenyl)-1,2,3,3a,4,9b-hexahydro-cyclopenta[*c*]chromen-8-ol;


including the enantiomers or a pharmaceutically acceptable salt thereof.

4. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




and the enantiomers or a pharmaceutically acceptable salt thereof.

5. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




and the enantiomers or a pharmaceutically acceptable salt thereof.

6. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

7. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

8. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

9. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

10. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

11. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

12. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

13. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ a pharmaceutically acceptable salt thereof.

14. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ a pharmaceutically acceptable salt thereof.

15. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ a pharmaceutically acceptable salt thereof.

16. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ a pharmaceutically acceptable salt thereof.

17. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

18. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

19. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

20. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

21. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

22. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

23. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

24. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ a pharmaceutically acceptable salt thereof.

25. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ a pharmaceutically acceptable salt thereof.

26. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ a pharmaceutically acceptable salt thereof.

27. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

28. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

29. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

30. (Currently Amended) A compound according to claim 1 wherein the compound is of the formula:



~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

31. (Currently Amended) A compound according ~~of the~~ to the formula II:



(II)

wherein:

G and G' are each CH₂, C=O, C=CH₂, CHC₁-C₆alkyl or CF₂; with the proviso that when G' is other than CH₂, G must be CH₂ and that when G is other than CH₂, G' must be CH₂;


~~including the enantiomers and the~~ or a pharmaceutically acceptable salt thereof.

32. (Currently Amended) A compound selected from the group ~~comprising~~ consisting of:

- a. (6S, 6aR, 10aS)-2-Hydroxy-6-(4-hydroxy-phenyl)-6,6a,7,8,10,10a-hexahydro-benzo[c]chromen-9-one;
- b. (6aR, 6S, 10aS)-6-(4-Hydroxy-phenyl)-9-methylene-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-2-ol;
- c. (6aR, 6S, 9S, 10aS)-6-(4-Hydroxy-phenyl)-9-methyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-2-ol;
- d. (6aR, 6S, 9R, 10aS)-6-(4-Hydroxy-phenyl)-9-methyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-2-ol;
- e. (6aR, 6S, 10aS)-9,9-Difluoro-6-(4-hydroxy-phenyl)-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-2-ol; and
- f. (6aR, 6S, 10aS)-2-Hydroxy-6-(4-hydroxy-phenyl)-6a,9,10,10a-tetrahydro-6H,7H-benzo[c]chromen-8-one;


~~including their enantiomers or~~ a pharmaceutically acceptable salt thereof.

33. (Currently Amended) A compound according to claim 31 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

34. (Currently Amended) A compound according to claim 31 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

35. (Currently Amended) A compound according to claim 31 wherein the compound is of the formula:




~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

36. (Currently Amended) A compound according to claim 31 wherein the compound is of the formula:



~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

37. (Currently Amended) A compound according to claim 31 wherein the compound is of the formula:



~~and the enantiomers~~ or a pharmaceutically acceptable salt thereof.

38. (Currently Amended) A pharmaceutical composition comprising a compound of ~~according to any of Claims 1 through 37~~ Claim 1 and a pharmaceutically acceptable carrier.

39. (Cancelled)

40. (Cancelled)

41. (Currently Amended) A method of treating prostate cancer in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of ~~any of Claims 1 through 38~~ Claim 1.

42. (Currently Amended) A method of treating benign prostatic hyperplasia (BPH) in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of ~~any of Claims 1 through 38~~ Claim 1.

43. (Currently Amended) A method according to ~~any of Claims 39-42~~ Claim 42 wherein said patient is a human.

44. (Cancelled)

45. (New) A pharmaceutical composition comprising a compound of Claim 3 and a pharmaceutically acceptable carrier.

46. (New) A pharmaceutical composition comprising a compound of Claim 31 and a pharmaceutically acceptable carrier.

47. (New) A pharmaceutical composition comprising a compound of Claim 32 and a pharmaceutically acceptable carrier.